Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 1.00 |
| ▸ | NCF1 | P14598 | 6/20 | 0.52 |
| ▸ | NOS2 | P35228 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NCK1 | P16333 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18317038 | 1.00 | BACE1 (1.00) | BACE1NCF1NOS2CYP1A2CYP2C19 | |
| SCHEMBL9312 | 0.84 | BACE1 (1.00) | BACE1NCF1NOS2PABPC1PLAU | |
| Hydrochloric Acid SCHEMBL14245319 | 0.83 | BACE1 (0.96) | BACE1NCF1NOS2PABPC1PLAU | |
| SCHEMBL703102 | 0.77 | BACE1 (0.63) | BACE1CYP1A2CYP2C19HTTPABPC1 | |
| SCHEMBL29471057 | 0.77 | BACE1 (0.63) | BACE1CYP1A2CYP2C19HTTPABPC1 | |
| SCHEMBL28417141 | 0.76 | BACE1 (0.61) | BACE1CYP1A2CYP2C19HTTPABPC1 | |
| SCHEMBL7014346 | 0.76 | PLAU (0.71) | BACE1NCF1NOS2HTTPLAU | |
| SCHEMBL28184246 | 0.75 | BACE1 (0.60) | BACE1CYP1A2CYP2C19HTTPABPC1 | |
| SCHEMBL22743051 | 0.74 | BACE1 (0.59) | BACE1CYP1A2CYP2C19HTTPABPC1 | |
| SCHEMBL24954263 | 0.73 | BACE1 (0.57) | BACE1NCF1NOS2PLAUNCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11883367-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-30 | — | — | US | disclosed |
| US-20230071711-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-09 | — | — | US | disclosed |
| EP-3724190-B1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | LUPIN LTD (IN) | 2022-07-06 | — | — | EP | disclosed |
| US-11318157-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11318157-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | BACE1 1835/4885NCF1 2096/4885NOS2 1814/4885 |
| US-20230071711-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | BACE1 2184/4885NCF1 1596/4885NOS2 688/4885 |
| US-11883367-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | BACE1 2198/4885NCF1 1797/4885NOS2 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.